PanOptica snags $45 mln Series B funds

PanOptica said Tuesday that it has closed up to $45 million in Series B funding. Novo Ventures and Third Rock Ventures led the round with participation from SV Life Sciences. Headquartered in Bernardsville, NJ, PanOptica is a biopharmaceutical firm focused on ophthalmology therapies.

SAGE Therapeutics nabs $38 mln Series C funds

SAGE Therapeutics has closed $38 million in Series C financing. Investors included OrbiMed Advisors, EcoR1 Capital Management, Foresite Capital Management, Third Rock Ventures and ARCH Venture Partners. Based in Cambridge, Mass., SAGE Therapeutics is a biopharmaceutical company focused on treating orphan central nervous system disorders.

SAGE Therapeutics secures $20m Series B financing

Biopharmaceutical company SAGE Therapeutics has secured a $20 million Series B financing from investors ARCH Venture Partners and Third Rock Ventures, bringing the total raised to $57.8 million since launch in 2011. The Series B financing will accelerate clinical and preclinical efforts to continue to advance SAGE’s pipeline programs in CNS disorders.

Taris Biomedical Raises $12.5 Million

Taris Biomedical, a specialty pharmaceutical company developing therapies to treat bladder diseases, has raised a fresh $12.5 million in funding from its existing investors, Flagship Ventures, Flybridge Capital Partners, Polaris Partners, and Third Rock Ventures. With the new funding, Taris, based in Lexington, Mass., has raised $49.8 million altogether.

Cibiem Appoints President and CEO

Medical device company Cibiem has appointed Ken Martin to president and chief executive officer. Martin will succeed Cibiem co-founder Howard R. Levin who will continue his active involvement within the company and as a member of its board of directors.The company is backed by SV Life Sciences and Third Rock Ventures.

Kala Pharmaceuticals Secures $11.5m Series A

Kala Pharmaceuticals has secured $11.5 million in Series A equity financing through new and existing investors. New and lead investor Crown Venture Fund the venture capital arm of the Crown family of Chicago, joined Kala’s existing investors including Lux Capital Management, Polaris Venture Partners and Third Rock Ventures.

Shire Acquires Lotus Tissue Repair

Shire has signed an agreement to acquire Lotus Tissue Repair. The business is a private biotechnology company launched in 2011 by a team of biotechnology entrepreneurs and life sciences investor, Third Rock Ventures.

Blueprint Medicines Makes Chris Varma Permanent CEO; Names Daniel Lynch Executive Chairman

Blueprint Medicines, a Cambridge, Mass.-based company that’s developing cancer therapies, has made Chris Varma, its founding president and an entrepreneur-in-residence at Third Rock Ventures, its permanent president and CEO. The company has also named Daniel Lynch as executive chairman of its board. Lynch spent nearly five years at ImClone Systems, including as CEO and CFO.

Igenica Closes $33 Million in Series C Funding

California-based antibody biopharma company Igenica has raised $33 million in a Series C round led by new investor Third Rock Ventures. Existing backers The Column Group, Orbimed Advisors and 5AM Ventures participated in the round; Igenica has raised about $55 million to date. PRESS RELEASE: BURLINGAME, Calif., June 12, 2012 /PRNewswire/ — Igenica, Inc., a […]

PEHUB Community

Join the 12493 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget